Cocrystal Pharma Inc. has announced positive results from a Phase 1 clinical study of its oral, direct-acting pan-viral inhibitor CDI-988. The study, which was randomized, double-blinded, and placebo-controlled, demonstrated that all doses of CDI-988, ranging from 100 mg to 1200 mg, were well tolerated. These findings were presented at the 2025 Military Health System Research Symposium. CDI-988 is being developed as a potential prophylaxis and treatment for norovirus, addressing a critical unmet medical need due to the lack of approved treatments or vaccines for the virus. Cocrystal Pharma plans to initiate a Phase 1b study with norovirus-infected healthy subjects later this year. The development of CDI-988 is supported by Cocrystal's proprietary structure-based platform technology, aimed at creating novel broad-spectrum antivirals.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。